Business Description
Amylyx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
43 Thorndike Street, Cambridge, MA, USA, 02141
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.49 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48 | |||||
| 9-Day RSI | 57.48 | |||||
| 14-Day RSI | 61.3 | |||||
| 6-1 Month Momentum % | -13.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.58 | |||||
| Quick Ratio | 9.58 | |||||
| Cash Ratio | 9.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -44.77 | |||||
| ROIC % | -1939.32 | |||||
| ROC (Joel Greenblatt) % | -2573.49 | |||||
| ROCE % | -50.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.98 | |||||
| Price-to-Tangible-Book | 5.99 | |||||
| EV-to-EBIT | -15.9 | |||||
| EV-to-EBITDA | -15.91 | |||||
| EV-to-Forward-Revenue | 83.46 | |||||
| EV-to-FCF | -17.49 | |||||
| Price-to-Net-Current-Asset-Value | 6.21 | |||||
| Price-to-Net-Cash | 6.51 | |||||
| Earnings Yield (Greenblatt) % | -6.29 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AMLX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.443 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 61.3 | ||
| 14-Day ATR ($) | 2.010546 | ||
| 20-Day SMA ($) | 23.153 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 6.51 - 33.41 | ||
| Shares Outstanding (Mil) | 58.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amylyx Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||